Symbiomix assembled clinical investigators and study coordinators in Dallas, Texas, for an Investigator Meeting in preparation for initiating a Phase 2 clinical trial of SYM-1219 in women with bacterial vaginosis (BV). SYM-1219 is being developed as the first oral one-and-done treatment for BV in the U.S. The trial will be a multi-center, prospective, randomized, double-blind, placebo-controlled Read more…